<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="patients with viral infections—approaches that can be applied to any" exact="infectious disease." post="A second reason for the popularity of antibodies in"/>
 <result pre="distinguish between closely related molecular targets. In the case of" exact="infectious disease," post="this selectivity can be absolute, since antibodies can be"/>
 <result pre="[11]. The dramatic clinical effect in subgroups of otherwise treatment-refractory" exact="cancer" post="patients has led to products with prices well in"/>
 <result pre="of US$10,000 per month [12]. Another recent milestone for an" exact="infectious disease" post="was the global approval of ibalizumab, a humanized mAb"/>
 <result pre="mediators that are overexpressed in disease, such as cytokines in" exact="rheumatoid arthritis" post="or cell-surface markers in oncology. For the anti-tumor necrosis"/>
 <result pre="that are overexpressed in disease, such as cytokines in rheumatoid" exact="arthritis" post="or cell-surface markers in oncology. For the anti-tumor necrosis"/>
 <result pre="oncology. For the anti-tumor necrosis factor (anti-TNF) antibodies used in" exact="rheumatoid arthritis," post="although there is an initial loading dose to reduce"/>
 <result pre="delivery of the subcutaneous approach, with a reasonable dose. In" exact="infectious disease," post="the biggest success story has been the use of"/>
 <result pre="to US$80/g [18]. For a public health application against an" exact="infectious disease" post="in an LMIC, an intramuscular or subcutaneous delivery would"/>
 <result pre="costs is difficult, but as a comparison, the recently launched" exact="malaria" post="vaccine provides less than 50% protection for 3 injections"/>
 <result pre="US$5 each. The programmatic cost of protecting a child from" exact="malaria" post="for a year in the Sahel using existing low-cost"/>
 <result pre="developed and marketed for respiratory syncytial, varicella zoster, vaccinia, and" exact="hepatitis" post="B viruses (HBVs) [27, 28]. Historically, immune responses against"/>
 <result pre="understood, for instance, with therapeutic opportunities against viruses such as" exact="rabies" post="that rely on passive immunization. mAbs that target the"/>
 <result pre="is especially effective in infections, such as those with the" exact="rabies" post="virus, which avoids apoptosis of infected neurons while killing"/>
 <result pre="approved in the European Union or the US for cytomegalovirus," exact="hepatitis" post="viruses A and C, and postexposure prophylaxis against measles,"/>
 <result pre="and C, and postexposure prophylaxis against measles, rabies, rubella, and" exact="tetanus" post="[31]. These approaches appear most suitable for virus infections"/>
 <result pre="marketed antibodies that target bacteria, and these target toxins, namely" exact="anthrax" post="and Clostridium cytotoxin [27]. This paucity may be due"/>
 <result pre="[63]. Abbreviations: BCG, Bacillus Calmette–Guérin; CIS43, circumsporozoite protein 43; HBV," exact="hepatitis" post="B virus; mAb, monoclonal antibody; mutFc, mutated Fragment crystallizable"/>
 <result pre="monoclonal antibody; mutFc, mutated Fragment crystallizable region; TB, tuberculosis; VL," exact="visceral leishmaniasis" post="Schistosomiasis Human schistosomiasis is caused by infection, mainly with"/>
 <result pre="antibody; mutFc, mutated Fragment crystallizable region; TB, tuberculosis; VL, visceral" exact="leishmaniasis" post="Schistosomiasis Human schistosomiasis is caused by infection, mainly with"/>
 <result pre="Fragment crystallizable region; TB, tuberculosis; VL, visceral leishmaniasis Schistosomiasis Human" exact="schistosomiasis" post="is caused by infection, mainly with one of 4"/>
 <result pre="with schistosomal infections is difficult to calculate. Comorbidities linked to" exact="anemia" post="are common, and infection with S. haematobium can lead"/>
 <result pre="molecule inhibitor [66]. No target-product profile (TPP) for prophylaxis against" exact="schistosomiasis" post="has been published, but it is possible to start"/>
 <result pre="80 to 200 μg in mice [19]. Target identification for" exact="schistosomiasis" post="is not straightforward. Unlike malaria, the vaccine field offers"/>
 <result pre="a noninflammatory Th2 response. The clinical use of anti-IL17 in" exact="rheumatoid arthritis" post="clearly exacerbates fungal infection [91], although it remains to"/>
 <result pre="noninflammatory Th2 response. The clinical use of anti-IL17 in rheumatoid" exact="arthritis" post="clearly exacerbates fungal infection [91], although it remains to"/>
 <result pre="spreads hematogenously to the cerebrospinal fluid and brain to cause" exact="meningitis" post="and meningoencephalitis, adding the complexity of crossing the blood–brain"/>
 <result pre="kexin-like protein KEX1, was able to prevent transmission of Pneumocystis" exact="pneumonia" post="from infected to susceptible cohoused mice, demonstrating the feasibility"/>
 <result pre="significant morbidity and mortality, particularly in patients with HIV or" exact="tuberculosis" post="(TB) infection [114]. A recent paper demonstrated the cloning"/>
 <result pre="of the gap between a pathogen’s prevalence and burden. Mycobacterium" exact="tuberculosis" post="spreads easily among human populations; presently, about one-third of"/>
 <result pre="further consideration�? [128]. Malaria The role of protective antibodies in" exact="malaria" post="was demonstrated over 40 years ago with the finding"/>
 <result pre="development of infection in other mice [129]. The TPPs for" exact="malaria" post="are well described [130, 131]. These include a profile"/>
 <result pre="well described [130, 131]. These include a profile for seasonal" exact="malaria" post="chemoprevention, a treatment successfully launched in sub-Saharan Africa in"/>
 <result pre="monthly to children during the rainy season. Antibody therapeutics for" exact="malaria" post="could (1) prevent the entry (initial infection) of the"/>
 <result pre="transmission cycle). One difficulty in targeting the merozoites in symptomatic" exact="malaria" post="is that the extracellular phase of the pathogen is"/>
 <result pre="discovery of therapeutic mAbs [143]. Leishmaniasis In the case of" exact="visceral leishmaniasis" post="(VL), IL-10 and glucocorticoid-induced TNF-receptor–related protein have been considered"/>
 <result pre="of therapeutic mAbs [143]. Leishmaniasis In the case of visceral" exact="leishmaniasis" post="(VL), IL-10 and glucocorticoid-induced TNF-receptor–related protein have been considered"/>
 <result pre="conclusions Although mAbs have made a massive impact in controlling" exact="autoimmune disease," post="inflammation, and cancer, the relative impact in the world"/>
 <result pre="inflammation, and cancer, the relative impact in the world of" exact="infectious disease" post="has largely been confined to viral diseases. The use"/>
 <result pre="natural response to infection. Studies in animal models of chronic" exact="malaria" post="infection led to the observation that this results in"/>
 <result pre="and HBV infection [11]. This has important implications for any" exact="infectious disease" post="in which a single infection does not drive a"/>
 <result pre="dominate the human B cell response against 2009 pandemic H1N1" exact="influenza" post="virus infection. J Exp Med. 2011;208(1):181–93. 10.1084/jem.2010135221220454 10HayM, ThomasDW,"/>
 <result pre="as a Single Dose to Healthy Preterm Infants. The Pediatric" exact="infectious disease" post="journal. 2018;37(9):886–92. 10.1097/INF.000000000000191629373476 16KelleyB.Industrialization of mAb production technology: the"/>
 <result pre="to protect against malaria. Malar J. 2018;17(1):40210.1186/s12936-018-2549-1 .30384848 20UNITAID. Seasonal" exact="malaria" post="chemoprevention for children in the Sahel. https://unitaidorg/project/seasonal-malaria-chemo-prevention-children-sahel/#en. 2017. [cited"/>
 <result pre="BalthasarJP. Mechanistic considerations for the use of monoclonal antibodies for" exact="cancer" post="therapy. Cancer biology &amp;amp; medicine. 2014;11(1):20–33. 10.7497/j.issn.2095-3941.2014.01.00224738036 22KontermannRE. Strategies"/>
 <result pre="Vaccine. 2013;31(12):1553–9. 10.1016/j.vaccine.2013.01.025 .23370150 29LafonM.Immune evasion, a critical strategy for" exact="rabies" post="virus. Developments in biologicals. 2008;131:413–9. .18634503 30MimuraY, KatohT, SaldovaR,"/>
 <result pre="10.1086/507547 .16983626 52GaoY, ZhangTY, YuanQ, XiaNS. Antibody-mediated immunotherapy against chronic" exact="hepatitis" post="B virus infection. Human vaccines &amp;amp; immunotherapeutics. 2017;13(8):1768–73. 10.1080/21645515.2017.131902128521640"/>
 <result pre="RTS'S Clinical Trials Partnership. Efficacy and safety of the RTS,S/AS01" exact="malaria" post="vaccine during 18 months after vaccination: a phase 3"/>
 <result pre="WeidleC, Flores-GarciaY, FlynnBJ, SackBK, et al.A human monoclonal antibody prevents" exact="malaria" post="infection by targeting a new site of vulnerability on"/>
 <result pre="WeidleC, Flores-GarciaY, FlynnBJ, SackBK, et al.A human monoclonal antibody prevents" exact="malaria" post="infection by targeting a new site of vulnerability on"/>
 <result pre="65HotezPJ, HarrisonW, FenwickA, BustinduyAL, DuckerC, Sabina MbabaziP, et al.Female genital" exact="schistosomiasis" post="and HIV/AIDS: Reversing the neglect of girls and women."/>
 <result pre="CordingleyJS, DaltonPR, DunneDW, KariukiHC, et al.Immunity after treatment of human" exact="schistosomiasis" post="mansoni. II. Identification of resistant individuals, and analysis of"/>
 <result pre="al.Pilot-scale production and characterization of paramyosin, a vaccine candidate for" exact="schistosomiasis" post="japonica. Infect Immun. 2008;76(7):3164–9. 10.1128/IAI.00409-0818426875 80van DiepenA, Van der"/>
 <result pre="WongwitW, Pattara-ArechachaiJ, et al.Comparison of the protective efficacy on mekongi" exact="schistosomiasis" post="in mice induced by antigens derived from cercariae, schistosomulae"/>
 <result pre="10.1098/rstb.2015.046828080991 91SaunteDM, MrowietzU, PuigL, ZachariaeC. Candida infections in patients with" exact="psoriasis" post="and psoriatic arthritis treated with interleukin-17 inhibitors and their"/>
 <result pre="MrowietzU, PuigL, ZachariaeC. Candida infections in patients with psoriasis and" exact="psoriatic arthritis" post="treated with interleukin-17 inhibitors and their practical management. The"/>
 <result pre="PuigL, ZachariaeC. Candida infections in patients with psoriasis and psoriatic" exact="arthritis" post="treated with interleukin-17 inhibitors and their practical management. The"/>
 <result pre="93DromerF, CharreireJ, ContrepoisA, CarbonC, YeniP. Protection of mice against experimental" exact="cryptococcosis" post="by anti-Cryptococcus neoformans monoclonal antibody. Infect Immun. 1987;55(3):749–52. 3546140"/>
 <result pre="PiccoliL, BarbieriS, et al.A public antibody lineage that potently inhibits" exact="malaria" post="infection through dual binding to the circumsporozoite protein. Nat"/>
 <result pre="Dis. 2016;10(2):e000441510.1371/journal.pntd.000441526872334 145DyckL, MillsKHG. Immune checkpoints and their inhibition in" exact="cancer" post="and infectious diseases. Eur J Immunol. 2017;47(5):765–79. Epub 2017/04/11."/>
</results>
